🇺🇸 FDA
Pipeline program

SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

20230005

Phase 3 small_molecule active

Quick answer

SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL for Metastatic castration-resistant prostate cancer (mCRPC) is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Metastatic castration-resistant prostate cancer (mCRPC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials